12:00 AM
 | 
May 04, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DAG for Injection: Additional Phase I/II data

Data from 6 patients with refractory GBM in the 8th cohort of an open-label, U.S. Phase I/II trial showed that 50 mg/m 2 IV VAL-083 given on days 1-3 of a 21-day cycle led to dose-limiting toxicities (DLTs) of grade 3/4 thrombocytopenia, which resolved rapidly and spontaneously without concomitant treatment. Of the...

Read the full 236 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >